Encainide
Encainide is a class Ic antiarrhythmic agent used in the management of cardiac arrhythmias. It works by blocking sodium channels in the heart, which helps to stabilize the cardiac cell membrane and reduce abnormal electrical activity.
Mechanism of Action[edit | edit source]
Encainide exerts its effects by inhibiting the fast inward sodium current during phase 0 of the cardiac action potential. This action results in a decrease in the rate of rise of the action potential, leading to a slower conduction velocity in the His-Purkinje system and the ventricular myocardium. By stabilizing the cardiac cell membrane, encainide helps to prevent and treat various types of arrhythmias, including ventricular tachycardia and supraventricular tachycardia.
Pharmacokinetics[edit | edit source]
Encainide is administered orally and is rapidly absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism in the liver, resulting in the formation of active metabolites. The drug and its metabolites are primarily excreted in the urine.
Clinical Use[edit | edit source]
Encainide is indicated for the treatment of life-threatening ventricular arrhythmias. However, its use has declined due to concerns about its safety profile, particularly after the results of the Cardiac Arrhythmia Suppression Trial (CAST) showed an increased risk of mortality in patients treated with encainide and other class Ic antiarrhythmics.
Adverse Effects[edit | edit source]
Common adverse effects of encainide include dizziness, nausea, and headache. More serious side effects can include proarrhythmia, heart failure, and hepatic dysfunction. Due to these potential risks, encainide is generally reserved for patients who have not responded to other antiarrhythmic therapies.
Contraindications[edit | edit source]
Encainide is contraindicated in patients with pre-existing second-degree or third-degree heart block, cardiogenic shock, and severe bradycardia. It should be used with caution in patients with hepatic impairment and renal impairment.
History[edit | edit source]
Encainide was developed in the 1980s and was initially approved for use in the treatment of ventricular arrhythmias. However, its use has significantly declined following the results of the CAST study, which highlighted the potential risks associated with class Ic antiarrhythmics.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
CaptionSynonyms| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
